Glatiramer is the active portion of the drug, glatiramer acetate. Breastfeeding is not expected to result in clinically relevant exposure of the infant to the drug. Follow-up of infants indicates that maternal use of glatiramer acetate does not appear to cause any adverse effects in breastfed infants. Glatiramer acetate is generally considered safe by most experts and appears to be one of the preferred disease-modifying agents for treating multiple sclerosis during breastfeeding.[1-8] No special precautions appear to be required during breastfeeding while using glatiramer and breastfeeding can resume immediately after injection.[9]